Ncardia
ncardia.com
Actively hiring
Cell & Gene Therapy
Biotechnology
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
11-50
employees, estimated range
Grants
$4.6M
4 grants · CORDIS
Backers
1
Vesalius Biocapital
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 25, 2025
Launched Ncardia launches Ncyte NHP-C vCardiomyocytes to advance cardiac safety research · pharmabiz.com
Oct 9, 2024
Launched Ncardia Launches Panel of Ready-to-Use Assays to Streamline Screening and Selection of New Therapeutic Candidates · FinanzNachrichten.de
Feb 24, 2022
New executive Ncardia hires Holt as chief commercial officer · MM+M - Medical Marketing and Media
Jan 23, 2020
Partnership Ncardia and Bluerock Therapeutics announce collaboration agreement and licensing of process development technologies for the manufacture of iPSC-deri… · NewsMedical
Nov 1, 2016
Won a grant $601k · CORDIS
Jul 1, 2016
Won a grant $3.5M · CORDIS
Jun 1, 2015
Won a grant $174k · CORDIS
Jun 1, 2015
Won a grant $369k · CORDIS
Funding rounds
Registers and programsofficial lists and records that name the company
| Legal entity | Ncardia Services B.V. | its site |
Backed byfrom the funds' portfolios and accelerator catalogs
Vesalius Biocapital Similar startupsby what they do, their industry and backers
Discover GC Therapeutics, a pioneer in scalable, cutting-edge cell therapies designed to revolutionize treatment across a broad range of…
Aegle Therapeutics is a pioneer in regenerative medicine developing extracellular vesicle (EV) therapy to meaningfully improve the lives of…
Co-founded in 2017 by two pioneers in genome editing technology, Qihan Biotech has world-leading capabilities in multiplexable genome…
Designer cell therapies for pets first and their people next.
Shinobi Therapeutics is transforming cell therapy with scalable, immune-evasive iPSC-derived treatments for cancer and autoimmune diseases.
Our powerful, patented genome engineering technologies and iPSC expertise enable the next wave of advanced therapeutics.
News
Ncardia launches Ncyte NHP-C vCardiomyocytes to advance cardiac safety research
Ncardia launches Ncyte NHP-C vCardiomyocytes to advance cardiac safety research
Read more
Report
Ncardia Launches Ncyte Microglia to Advance Research in Neurodegenerative Diseases
Ncardia Launches Ncyte Microglia to Advance Research in Neurodegenerative Diseases
Read more
Report
Ncardia Launches Panel of Ready-to-Use Assays to Streamline Screening and Selection of New Therapeutic Candidates
New assays based on iPSC help accelerate drug discovery by giving drug innovators in neurodegenerative diseases high quality data on a broad range of disease-relevant read-outs Ncardia, a leading
Read more
Report
Ncardia and Cellistic recruit Gustavo Mahler to lead the businesses through their next phase of growth
Ncardia and Cellistic recruit Gustavo Mahler to lead the businesses through their next phase of growth
Read more
Report
Pro access
Upgrade to see all 9 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.